[estiv] ESTAF updates
- From: Secretary ESTIV <secretariat@xxxxxxxxx>
- To: "estiv@xxxxxxxxxxxxx" <estiv@xxxxxxxxxxxxx>
- Date: Fri, 24 May 2013 22:59:10 +0200
Dear ESTIV Members,
It gives me great pleasure to inform you of the following:
1) EURL ECVAM Recommendation on the 3T3 NRU assay for acute oral toxicity
testing
Following amendments in response to restricted and public commenting rounds,
the 3T3 NRU Recommendation has now been published on the recommendation section
of the EURL ECVAM website
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-recommendations
2) EURL ECVAM Recommendations
Two EURL ECVAM recommendations are available for commenting:
• Direct Peptide Reactivity Assay (DPRA) for skin sensitisation testing,
based on an ECVAM-coordinated prevalidation study
• BHAS42 variant of the Cell Transformation Assay using the BHAS42 (ras
oncogene transfected/initiated) cell line. The latter recommendation is based
on a Japanese validation study which has undergone ESAC peer review.
Later this year the following recommendations for commenting will be forwarded
to you:
• Zebrafish Embryo Toxicity Test (ZFET) supporting acute aquatic
toxicity testing (based on a OECD-led study, coordinated in part, by EURL ECVAM
and peer reviewed by ESAC)
• Keratinosens Assay for skin sensitisation testing. This assay has been
validated by Givaudan SA, was submitted to and evaluated by EURL ECVAM and
subsequently peer reviewed by ESAC.
Please do not hesitate to contact me at
secretariat@xxxxxxxxx<mailto:secretariat@xxxxxxxxx> should you have any
questions or comments
Kind regards
Alison Gray
ESTIV secretary
Other related posts:
- » [estiv] ESTAF updates - Secretary ESTIV
